profit from every $100 of sales.
$0$100
Codexis
$1.16+21.07% today
-28.8% in 1 year
1-year low $0.961-year high $2.85
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Codexis sold, what it kept, and what it did with the cash.
Sales went from $139 million in 2022 to $70.4 million in 2025, with -$44.0 million of profit last year.
SalesProfit
Codexis vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Codexis | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Codexis's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 139 | 70 | 59 | 70 | |
| 101 | 57 | 43 | 61 | |
| -32 | -55 | -58 | -38 | |
| -26 | -58 | -50 | -34 | |
| -34 | -76 | -65 | -44 | |
| -0.51 | -1.12 | -0.89 | -0.50 | |
| 72.6% | 81.7% | 72.6% | 86.7% | |
| -22.9% | -78.1% | -98.3% | -54.5% | |
| -24.2% | -108.7% | -110.0% | -62.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 250 | 137 | 149 | 148 |
| Cash | 114 | 65 | 19 | 51 |
| Total debt | 44 | 16 | 60 | 73 |
| Total liabilities | 106 | 50 | 82 | 97 |
| 145 | 87 | 67 | 51 | |
| 65 | 68 | 73 | 87 | |
| -13.3% | -49.2% | -34.2% | -25.0% | |
| -23.2% | -88.0% | -97.5% | -87.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 11 | -53 | -49 | -19 | |
| 8 | 4 | 4 | 4 | |
| 3 | -57 | -54 | -24 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 15 | 10 | 13 | 10 |
Valuation
- –
- –
- –
- 5.3×
- 1.8×
- –
- –
- -18.8%
- -34.6%
- 0.0%
Profitability
- 86.7%
- -54.5%
- -62.5%
- -21.9%
- -22.0%
- -37.8%
- -68.1%
- -24.7%
- -22.6%
- 65.2%
Growth
- −20.2%
- –
- +55.6%
- –
- +7.8%
Financial health
- –
- 1.69
- 56.4%
- -10.0×
- 5.36
- 5.23
- 0.60
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 946
Bottom 7%of 871
Bottom 5%of 867
Bottom 5%of 986
What analysts expect
- Average price target
- $5.00
- Range
- $5.00 – $5.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.10 | -0.11 | +9.1% |
| Mar 11, 2026 | 0.11 | 0.01 | +1,000.0% |
| Nov 6, 2025 | -0.22 | -0.15 | −46.7% |
| Aug 13, 2025 | -0.16 | -0.17 | +5.9% |
| May 14, 2025 | -0.25 | -0.20 | −25.0% |
| Feb 27, 2025 | -0.13 | -0.04 | −225.0% |
| Oct 31, 2024 | -0.29 | -0.25 | −16.0% |
| Aug 8, 2024 | -0.32 | -0.26 | −23.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
24No pass
Benjamin Graham
31No pass
Philip Fisher
36No pass
Peter Lynch
15No pass
Joel Greenblatt
2No pass
Charlie Munger
24No pass
Terry Smith
28No pass
Questions about Codexis
Is Codexis a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Codexis AI analysis
What does Codexis do?
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It is in Biotechnology.
Does Codexis pay a dividend?
No. Codexis does not pay a dividend at the moment.
Is Codexis stock halal?
No. Codexis does not pass our halal screen: its debt is 58% of its market value, at or above the 33% limit. How we check
How has Codexis stock done over the past year?
Down 28.8% over the past twelve months, to $1.16. It traded between $0.96 and $2.85 and is 59.3% below its high.
Who are Codexis's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Codexis's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.